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The culture of virology
Diagnostic virology is classically defined by the use of cell 
culture to grow viruses. This technique involves the use of 
cells, either primary (derived from fresh tissue and propagated 
only a few times) or continuous, which are generally cancer 
cells. An example of a cancerous cell line is HeLa, which has 
been in use for decades and propagated in laboratories around 
the world. The major advantage of primary cell culture is 
that it closely resembles the cells that viruses infect naturally; 
consequently, many viruses grow best in these cells. The 
foremost examples are respiratory viruses such as influenza 
and parainfluenza. Some continuous cell lines are suitable 
for other viruses, which is advantageous for the laboratory 
because of their ease of use, their uninterrupted availability 
and their reliability.  
Cell culture has its problems (Table I). Primary cells have a 
major disadvantage in that they need to be sourced from tissue 
which may be available only unreliably, such as fetal lung 
or foreskin. One of the stalwarts of an old-fashioned routine 
diagnostic virology laboratory is primary rhesus monkey 
kidney, which is subject to strict animal laws (dialysis services 
for monkeys are in short supply), is less easy to source, and 
is often infected with monkey viruses, resulting in a loss of 
efficiency for growing other viruses due to competition.
Cell culture has other general problems. Firstly, many 
viruses do not grow in vitro, examples being all the hepatitis 
viruses, coronavirus (one of the commonest causes of colds) 
and parvovirus B19. Other viruses, such as cytomegalovirus 
(CMV) and rhinoviruses, can take many days to grow (if at 
all). This is a particular disadvantage when a rapid negative 
result is as important as a positive result. Secondly, cell culture 
can be contaminated by fungi and bacteria. The third and 
often underestimated problem is the cost in both staff and 
consumables to generate what can be a relatively small number 
of positive results (see below).
Of course, there have been alternative, rapid methods for 
diagnosing viruses for many years. First is antigen detection, 
which can be applied to a number of specimens, such as blood 
(for example, to detect HBsAg), stool (for example, to detect 
rotaviruses or noroviruses) and respiratory specimens (for 
example, direct fluorescence to detect influenza, adenovirus, 
parainfluenza viruses, CMV and respiratory syncytial virus 
(RSV). The antigen detection method has the advantage of 
speed but can be insensitive and, in the case of respiratory 
viruses, does not detect all potential pathogens and requires 
specimens with intact cells.
Another method is electron microscopy, which is quick 
if only a few specimens are to be investigated, and allows 
visualisation of all viruses, although large numbers are 
required and identification is at the family level only (e.g. 
herpes simplex virus (HSV) or varicella zoster virus (VZV) or 
Epstein-Barr virus (EBV) or CMV). Lastly, antibodies can be 
detected for many viral infections but these are subject to some 
fundamental drawbacks. Not everybody makes antibodies 
during virus infections and not all people make the same 
antibody to the same antigens. Antibodies are unreliable in 
immunocompromised patients. Antibodies often do not rise 
until the illness is well under way or improved, by which time 
the diagnosis may be of historical interest only. Furthermore, 
re-infection cannot be reliably diagnosed by antibodies (the 
negative predictive value is particularly poor), and validated 
serological tests are not available for every virus. For all these 
reasons, it has been accepted for many years that if virology is 
to be a clinically useful speciality, diagnosis needs to be quicker 
and all-encompassing, and the virus itself needs to be identified, 
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Table I. Is cell culture ‘catch-all’?
Only if …
1.    the cells are known to be sensitive
2.    there is continuous QA
3.    freezers do not break down
4a.  monkeys still get killed
Or …
4b.  we use many different cell lines
5.    they don’t have mycoplasma
6.    we can keep trained staff
7.    cells do not get infected with fungus
8.    as long as you do not want to ‘catch’ more than one virus
       Even then, they are globally insensitive
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not some surrogate marker of infection. When hybridisation 
techniques became available to detect the nucleic acid and 
thus the virus itself, these were seen as a potential answer to 
this problem, but have never lived up to their initial promise 
for diagnostic purposes. Sensitivity is poor, cross reactions are 
many and, until recently, some form of radioactively labelled 
probe was required. By the time hybridisation had ‘come of 
age’, various nucleic acid target amplification techniques had 
become available and substantial experience gained.
In our opinion, nucleic acid testing (NAT) (examples being 
the polymerase chain reaction (PCR), transcription-mediated 
amplification (TMA), nucleic acid sequence-based amplification 
(NASBA) and strand displacement amplification (SDA)) is 
the current saviour – the Harry Potter – of the speciality of 
clinical virology; paradoxically, it may also be the harbinger 
of its doom – its Lord Voldemort. Below, we focus on PCR as 
this is the technique which is most in use and in which we 
have the most experience. We focus particularly on in-house 
methodologies.
Precepts of PCR
Essentially, PCR is the process by which a known sequence of 
nucleic acid is enzymatically amplified to generate millions of 
copies of DNA of the same length and sequence. Details of the 
process can be found in many standard textbooks. The process 
can be applied to DNA viruses (such as HBV, adenoviruses, 
HSV) and RNA viruses (such as hepatitis C virus (HCV), 
HIV, influenza and rotaviruses) as long as the RNA is first 
converted into DNA using reverse transcriptase. Any sort of 
clinical sample can be used as source material for the nucleic 
acid, including blood, tissue, respiratory secretions, stool and 
CSF. The major advantage of the technique is that it is generic; 
fundamentally the same technology is applied to any sort of 
clinical sample to detect any sort of virus. However, there are a 
number of potential disadvantages, which are discussed below. 
Cost is often also cited as a major impediment to its widescale 
introduction; we also briefly discuss this.
In the last few years, major progress has been made in 
three areas. Automation is the first. There are now machines 
for nucleic acid extraction and others which can load up and 
amplify the nucleic acid and analyse the result. Nucleic acid 
extraction used to be a cumbersome process involving multiple 
operator processes to digest and remove all proteinaceous 
material, leaving only the nucleic acid in a reasonably pure 
state. Not only are the results more reliable, but in laboratories 
where large numbers of samples are tested manual extraction 
becomes impossible. The time has almost come when the 
entire process, from sample to result, will be automated. The 
second area is real-time PCR. By using fluorescence, either 
incorporated in a primer, into the growing DNA chain, or in 
the form of an oligonucleotide probe, the accumulation of 
amplified product can be monitored on a computer screen. 
This means that products do not have to be detected in an 
additional step called gel electrophoresis, and no manual 
manipulations are necessary, such as opening of reagent tubes 
that may be a potential source of contamination. In the recent 
past, a technique called nested PCR was commonly performed, 
whereby two rounds of PCR were done sequentially on each 
sample – this had the potential for contamination of the second 
round with products from the first round from a different 
patient, giving false-positive results. It was also more difficult 
to optimise and to run reliably. Real-time PCR also means 
that, by including viruses of known amount as controls, one 
can now quantitate the viral load of the input sample. With 
certain forms of real-time PCR, the process can take as little as 
20 minutes instead of 2 hours once the nucleic acid has been 
isolated. In our laboratories, the process takes just over an 
hour. The third is multiplexing. Multiple sets of primers and 
probes can be mixed together in one tube, allowing detection of 
one pathogen without the need for selecting which pathogens 
might be of interest. Technology now exists to allow detection 
of up to 20 or more potential pathogens1 without the need 
for one tube per target. This brings the cost per sample down 
considerably and, we would argue, actually makes NAT an 
economic prospect for any clinical sample. This approach also 
allows detection of more than one pathogen per sample, which 
occurs in up to 20% of respiratory samples.2
Real-time PCR has made the wholesale introduction of NAT 
an inevitability – and even obligatory – routine in laboratories. 
In the next few paragraphs, we present some experiences from 
a comprehensive molecularisation programme at our virus 
laboratories. Virus culture has consequently been relegated to 
specialist activities. Although the process began haltingly, the 
majority of this change was completed 2 - 3 years ago.  
Cerebrospinal fluid
It has been established for many years that HSV encephalitis 
is essentially a clinical diagnosis, because the virus (HSV1 
in most cases) will rarely be found by culture in CSF, and 
antibody titres take a week at least to appear, which is not very 
useful, and require a second CSF sample to be taken. Detection 
of HSV in CSF was one of the first clinical applications of 
PCR.3 Protocols for enteroviruses rapidly followed.4 In our 
laboratories an overall doubling at least in overall detection 
rates followed. With the decline in mumps incidence, this 
was not perceived to be an issue in Western Europe and the 
USA, but a surprising number of HSV2 and VZV infections 
were detected in patients with meningitis. Now that mumps is 
enjoying a resurgence, mumps PCR of CSF has become useful. 
Overall, it is rare for a culture-positive sample to be  missed 
by PCR, but some two to three times more diagnoses can be 
made using PCR. Although the expected pick-up rate will be 
lower, some laboratories have broadened the range of viruses 
targeted, such as CMV, EBV, JCV and human herpesvirus 
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(HHV) 6/7. HHV6 is particularly important in young children 
with febrile convulsions, and CMV and EBV can occasionally 
be found in the immunosuppressed patient. They either grow 
slowly or not at all in tissue culture, so CSF is a good example 
of PCR widening the range of detectable pathogens.
Genital samples
Chlamydia trachomatis (CT), human papillomavirus (HPV) and 
HSV are common and perhaps increasing in incidence. Culture 
for CT is slow and insensitive; enzyme-linked immunosorbent 
assay (ELISA) and immunofluorescence on swab material have 
low sensitivity, though acceptable specificity. Introduction 
of amplification procedures has dramatically increased the 
detection rate of these pathogens: by 30 - 40% for CT and 20% 
for HSV.5,6 HPV is a pathogen whose time is coming because 
of the ability to detect the virus using NAT. There are even 
debates as to whether cervical cytology should be abandoned 
in favour of NAT for HPV because of the sensitivity of NAT, its 
high negative predictive value and the finding that essentially 
all cervical cancers and the pre-cancerous lesions contain 
the virus.7 HPV cannot be cultured without heroic efforts. 
However, the ability to multiplex has allowed expansion of the 
targets that one can detect in a genital specimen. Why stop at 
CT when one can detect Neisseria gonorrhoeae and Mycoplasma 
genitalium in the same tube? Why bother with wet mounts 
for Trichomonas vaginalis when PCR is as sensitive8 and can be 
done in the same tube as other STDs on a vaginal swab for 
marginal additional cost? Syphilis, as with mumps, is making 
a comeback, and detection in vaginal swab increases the 
diagnostic rate significantly when added to antibody testing in 
blood.9
Respiratory secretions
Cell culture established the culturable causes of upper and 
lower respiratory tract infection. These include influenza, 
para-influenza, RSV and adenoviruses. However, not only 
has PCR increased the sensitivity of detection of all these 
pathogens, but it has also enabled us to detect viruses which 
we knew about but which were very seldom detected. With the 
advent of this technology, it has become apparent that these 
are significant causes of morbidity and, in some age groups, 
mortality. For example, rhinoviruses and coronaviruses 229E 
and OC27 were known to be the cause of the common cold 
in immunocompetent adults (even if they were only detected 
in less than 20% of cases) but they are now also known to be 
the major precipitating factor of asthma in children (found 
in 70% of samples) and, to a lesser degree, adults (perhaps 
50%).10 They are responsible for apnoeic episodes in infants, 
pneumonia in the immunocompromised and in the elderly, 
and for exacerbations of COPD. They also cause severe 
(sometimes fatal) disease in the imunocompromised. But PCR 
has brought an additional dimension to the diagnosis of these 
common conditions: it has enabled us to widen the range 
of viruses detected to include human metapneumovirus,11 
influenza C,12 a novel parvovirus (Bocavirus),13 the relatively 
new coronaviruses (SARS, NL63 and HKU)14-16 and two 
new polyomaviruses – WU and KI.17,18 Whether they are 
worth detecting is discussed below, but why culture and 
immunofluorescence are inadequate for this sample type in 
modern practice is absolutely clear.
Stool/faeces
Gastroenteritis, whether in outbreaks or sporadic, is most 
commonly caused by viruses. Epidemiological surveillance of 
these illnesses is highly insensitive, not only because a small 
proportion of cases are reported, but also because laboratory 
diagnosis is usually inadequate. The major cause is noroviruses 
(previously termed small, round structured viruses and 
then Norwalk-like viruses), but other significant causes are 
rotavirus, astroviruses, adenoviruses and sapoviruses (part 
of the Calicivirus family). None of these grow well in cell 
culture, but all can be detected by electron microscopy. Electron 
microscopy has the advantage of being quick on individual 
samples, but has the dual disadvantages of lack of sensitivity 
and the inordinate amount of technical time required to look 
at a large series of samples. Our, and others’, experience 
shows clearly that all of these viruses can be detected with 
greater sensitivity using PCR (Table II).19,20 However, it cannot 
be denied that electron microscopy is a very useful asset for 
the detection of new viruses or the exploration of unknown 
changes in cell cultures.
Table II. Increased sensitivity of PCR for viral gastroenteritis
Virus   EM   %  PCR/RT-PCR  % change (PCR-EM/EM)x100
Rotavirus    70               25.8           86                       +22.9
Norovirus     6  2.2           46                     +666.7
Adenovirus   12  4.4           40                     +233.4
Sapovirus     1  0.4             8                        +700
Astrovirus     3  1.1             7                      +133.3
Virus detected   92                33.9         187                      +103.3
No virus detected                 179                66.1          111                        -38.0
Total   271              100.0         298 
EM = electron microscopy; PCR = polymerase chain reaction; RT = reverse transcriptase.
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Blood
This has not been considered a useful sample for detecting 
viruses, except hepatitis B (an antigen test), HIV (an 
antigen test and growth in lymphocyte culture) and CMV 
in transplant patients (detection of antigen in lymphocytes 
and the occasional culture). The hepatitis viruses have never 
been detected in cell culture. PCR has changed all this. Now, 
we know that: enteroviruses can be detected in blood as a 
surrogate for CSF; HSV, EBV and adenovirus can be detected in 
plasma in immunosuppressed persons with serious disease; the 
amount of CMV, EBV, HIV, HCV and HIV in blood correlates 
with treatment outcome; and the best way of diagnosing HHV6 
is by PCR of a plasma sample.
Pros and cons
So: PCR is comprehensive. However, many reasons are cited 
for not introducing PCR (Table III). We discuss these issues in 
turn.
It is too complicated
This used to be true. Tests used to involve multiple steps 
with transfer of small volumes of reagents between vials, gel 
running and (often poor) interpretation of multiple bands. 
However, reagents are now available which allow a test to be 
set up –  even for detection of RNA – by adding aliquots from 
only two pre-supplied vials. Also, with the advent of real-time 
technology, a generic method has become increasingly suitable 
for a wide range of pathogens. Automated extraction has made 
it even easier. Results are now read by examining a curve on 
a screen. However, although it sounds ridiculously easy, there 
is a relatively slow learning curve that is not apparent for the 
introduction of other assays such as direct immunofluorescence 
(DIF) and ELISA tests. This is partly due to the need for small-
volume pipetting, the need to interpret results at the boundary 
of sensitivity, and the manipulation of electronic datasets on 
screen. On the other hand, culture was never easy!
PCR just stops working for no good reason
This, unfortunately, remains true though is less common as 
reagents improve. There are a number of reagents which, if 
missing from the ‘molecular soup’, or if inactive, will lead to 
failure of that assay. In our experience, primers, nucleotides 
and Taq polymerase can all ‘go off’ or, surprisingly commonly, 
manufacturers send a batch of reagents which do not work 
as well as the previous batch. The only way to circumvent 
this problem is, firstly, to have skilled staff with substantial 
experience in PCR who can sort out the problem and, secondly, 
be well prepared for such eventualities by having stocks of 
quality-controlled reagents in small volumes for at least 2 
months’ worth of assays in the freezers. In this way, the service 
is not interrupted while the problem is sorted out.
Contamination is a real problem
This is the single most important problem with large-scale 
introduction of PCR. Because of the sensitivity of the assay, 
either very small amounts of virus that may not have been 
in a particular patient’s specimen, plasmids containing the 
amplified sequence or the PCR product itself, can, if they find 
their way into the wrong tube, lead to a positive signal in a 
patient who does not have that virus. All laboratories and 
all personnel (as a generalisation) will have contamination 
problems during the learning phase. It can be very frustrating 
and, often, the offending contaminant is never identified. 
However, if a strict clean-up procedure and adherence to rules 
regarding gloves, gowns and separate pre-PCR and post-
PCR working areas are adhered to, contamination is rarely 
an issue in an experienced laboratory. It has also become less 
of a problem with real-time PCR as tests are performed in 
vessels that are sealed and do not need to be opened after 
amplification.
It takes too long compared with antigen detection
Table IV and Figs 1 and 2 compare the time taken to achieve 
a positive result by PCR compared with culture and antigen 
detection and how a real-time assay can take a similar amount 
of time to an antigen test, but can detect many more pathogens 
in that interval. On the other hand, a common time to achieve 
a true negative result by culture is 15 days. A typical run of 50 
CMV real-time PCR tests would now take 5 hours from the 
beginning of nucleic acid extraction to result generation. This is 
irrespective of whether the result is negative or positive.
Table III. Potential problems with PCR
It is too complicated
It just stops working for no good reason
Contamination is a real problem
It takes too long compared with antigen detection
How to process many samples in a reasonable time – multitip 1
Do all positives mean something? – transient infections 
Cost
Quality assurance is insufficient
What’s the point if you can’t do anything about it?
Whole viruses are needed for epidemiology and new virus discovery
Coping with genetic variability
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How to process many samples in a reasonable time
There are a number of approaches to this potential quandary. 
Firstly, one can multiplex, which means that reagents for 
multiple targets are placed within a single tube. Up to 4 targets 
can be simultaneously reliably assayed, limited by the number 
of dyes attached to probes that can be clearly distinguished 
(without cross-talk) by the electronics of the real-time 
instrument. It is unusual for more than two pathogens to be 
present at any one time, even in a stool or respiratory sample. 
Fig. 3 shows how two respiratory viruses can be tested for in 
one tube: a different fluorescent dye is used for each, allowing 
separate interpretation of the curves. An alternative is to test 
for the most likely pathogen first, followed by less likely causes 
if negative; this works particularly well during the influenza 
season, when 50% or so of all samples can be positive. Or one 
only tests for the 3 or 4 most common pathogens linked to a 
clinical scenario in a multiplex format. The disadvantage of 
the latter is that many viruses cause similar disease, so one 
will miss diagnoses. A newer approach is Luminex technology 
that can detect 20 or more targets using specific probes in a 
single tube.1,21  The approach that one of us has taken is to have 
a fixed menu of targets in a number of mutiplexes for each 
specimen type, almost without taking the clinical picture into 
account. This minimises mistakes and improves workflow as 
the staff have a relatively fixed work pattern every day.
Do all positives mean something?
Table V gives an indication of the relative value of PCR 
compared with culture. However, as PCR is so sensitive, a 
positive result could theoretically mean that the virus is just 
‘passing through’, or that non-viable nucleic acid is lingering 
on long after the active infection. As with any relatively new 
assay, the clinical utility has to be established by prospective 
testing linked to patient details. This is more difficult than it 
sounds because it is often not easy to get all relevant clinical 
information. Further, some virus infections are obviously 
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Fig. 1. Improved timings with technological development.
Fig. 2. Further improvement with real-time PCR. This details the full 
turnaround time from receipt until final printing of the report. All 
the results were available at least 24 hours before this; intervening 
weekends, when no work was done, are included. Only respiratory 
PCR results are detailed. The introduction of real-time PCR (on left of 
figure, from 2004) led to a significant reduction of processing time.
Table IV. Time comparison between a positive culture and NAT
Culture        NAT
Hours - 1 - 2 days   Influenza A, B   1 - 2 days
Hours - 3 days   RSV    1 - 2 days
Hours - 3 days   Paraflu 1, 2, 3   1 - 2 days
?    Paraflu 4    1 - 2 days
?    Influenza C   1 - 2 days
?    Metapneumovirus   1 - 2 days
2 - 3 days    SARS CoV   1 - 2 days
5 days    Rhinovirus   1 - 2 days
1 - 2 days    CMV    1 - 2 days
1 - 2 days    HSV    1 - 2 days
Days    Measles    1 - 2 days
Days    Adenoviruses   1 - 2 days
?    Coronaviruses   1 - 2 days
NAT = nucleic acid testing.
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asymptomatic and so it is only from experience that we will 
fully understand whether the finding of a viral sequence is 
always, or usually, clinically relevant. Rhinoviruses are a good 
example of this. Since introducing this assay, the number of 
rhinovirus detections has increased 20-fold, and clinicians often 
ask what it means when they receive a positive result. Clearly, 
the samples were sent to us in most cases because the patient 
was ill and we have to assume that it is causing the illness 
unless an alternative pathogen is identified (which is unusual).
What is required is exhaustive testing of asymptomatic 
persons to get some idea of the relative specificity of virus 
detection for clinical illness (the positive predictive value). The 
increased sensitivity of PCR means that viral nucleic acid will 
be present for a number of days longer than the viable virus (as 
detected in cell culture). In our experience, influenza RNA can 
be detected up to 14 days after the disease began, but after 7 
or 8 days, the detection rate drops. Clinicians are keen to send 
follow-up samples to monitor disappearance of virus in the 
mistaken belief that this correlates well with clinical recovery. 
One approach to this is to perform NAT as the initial diagnostic 
assay but then do an alternative assay such as DIF to monitor 
response to therapy (as one would expect this less sensitive 
test to become negative quickly with recovery). Parainfluenza 
virus can be positive intermittently for years without illness. 
However, when influenza is not around, we do not pick up 
any influenza virus positives in throat swabs, indicating that, 
at least for influenza, this is not an issue. For CMV in blood of 
bone marrow transplant recipients, the PCR usually becomes 
negative a few weeks after the institution of ganciclovir. A 
further, minor problem is that the primers used for a pathogen 
may detect related viruses which are not pathogenic. Some 
methods used to detect rhinoviruses also amplify vaccine 
strains of poliovirus. It is however clear that not only the 
qualitative result of the technique is important, but also that 
the quantification of viral samples will contribute significantly 
in solving these key questions regarding the presence of the 
virus and risk for disease. It is shown that with increasing viral 
levels, or changes of viral levels in time, a substantial increased 
risk for developing disease has been shown for viruses like 
CMV and EBV. 
Cost   
As with most things in the laboratory, the more you do, 
the cheaper it becomes. This is particularly applicable to 
equipment. Table VI provides a rough estimate of the relative 
cost per result in Europe of PCR compared with culture and 
DIF. The cost per positive result is particularly illuminating: 
this effect is because the number of positives is greatly 
enhanced by PCR. One also needs to include in any cost-
effectiveness analysis an estimate of the clinical and laboratory 
value of a negative result that is reliable and quick (and so 
does not require further costly investigations). An issue that 
currently has a negative effect on overall costs is the licensing 
fees that hospitals and companies have to pay to patent holders 
of new techniques such as real-time technology.
Quality assurance is insufficient
The recent European directive makes it clear that any 
laboratory which uses an in-house assay for in vitro diagnostics 
has to set up an internal quality assurance system, to be certain 
that the technique is performing at an acceptable level. This 
is one of the main reasons why large-volume in-house PCR 
assays need to be performed at large centres to begin with 
before they become routine and properly controlled and can 
then be done at smaller laboratories. There are good quality 
assessment systems, such as Quality Control for Molecular 
Diagnostics (qcmd.org), which enable individual laboratories to 
compare their performance in an anonymous manner against 
others. Unfortunately, the QA systems do not cover all the 
Table V. How useful are culture and real-time PCR for 
disease diagnosis?
Positive predictive value?
Culture   100%
NAT   We do not know  – ?90%
Negative predictive value?
Culture  30%
NAT   80%
Table VI. Back-of-an-envelope costs of diagnostic virology 
techniques for a respiratory sample
Consumables  DIF  54 euros
   Culture  61 euros
   PCR  16 euros
+ staff costs
Costs per positive result DIF  54 euros
   Culture  388 euros
   PCR  50 euros
What is the clinical and monetary value of a ‘true negative’??
Fig. 3. Real-time multiplex PCR. Two dyes with different wavelengths 
are added to the probes. The reaction takes place in one tube. By 
analysing results using one wavelength only, each result can be noted 
individually.

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viruses tested for in many laboratories. However, one should 
also realise that quality control issues are relevant for all kinds 
of viral diagnostics, including serology and virus culture.
What’s the point if you can’t do anything about it?
Information in itself is valuable. Knowing that a sample is 
positive for a virus should change the management of that 
patient. An implication of the increased sensitivity is that a 
negative result becomes more believable to the clinician, i.e. it 
has a high negative predictive value. For example, a negative 
HSV result in a genital swab indicates to the clinician that 
further investigation is required and that the illness may be 
due to some previously unrecognised illness. In addition, 
although HSV grows well in cell culture (it is the virological 
weed), it requires some 7 - 10 days of continuous culture 
before an experienced operator would be willing to declare the 
sample negative. With blind immunofluorescence techniques, 
this can be reduced to 2 - 3 days. PCR brings this date forward 
by 5 - 7 days in large laboratories, giving definite results in 
1 - 2 days. We live in the information age, and both doctors 
and patients should know what the diagnosis is if the illness 
is severe enough to warrant the time and cost involved in an 
office visit. In these days of requiring a financial justification 
for every technological advance, we propose that the cost of the 
test will be offset by savings on X-rays, return visits and, most 
importantly, misguided use of antibiotics. The introduction of 
an increasing number of antivirals has meant that one can now 
actively intervene if one has a positive result within a short 
time after the illness begins. Finally, the Public Health depends 
critically upon reliable information on infections provided in a 
useful timeframe. PCR delivers this.
Whole viruses are needed for epidemiology and 
new virus discovery
This is a more difficult criticism to rebuff, but it is only true for 
a few viruses. PCR protocols can be chosen so that the type of 
virus can be analysed for genotype or serotype by restriction 
enzyme digest of the PCR product. Similarly, tracing an 
outbreak is easily achievable by sequencing of PCR products. 
Characterisation of antigenicity cannot be done easily; 
however, for influenza, the most cited example of the value of 
cell culture, reverse genetic approaches are now available to 
clone the PCR product into a vector and subsequently produce 
RNA, and then viruses, in tissue culture. New viruses have 
been discovered by both culture and molecular approaches.
We suggest that such activities are highly specialist and 
should only be offered by large central reference facilities 
where suitably trained staff, the requisite skills and significant 
numbers of samples are available.
Coping with genetic variability
Virus culture should not be abolished completely – only for 
routine clinical diagnosis. It will be particularly important 
to monitor the sequence of circulating viruses, after culture, 
to ensure that point mutations do not arise that decrease the 
sensitivity of NAT assays (Fig. 4). An alternative approach 
is to use PCR protocols that amplify a long stretch of nucleic 
acid to include the primer and probe binding regions and then 
sequence those critical sites. Any variability that has arisen can 
be detected and the reagents suitably altered.  
The future
Viral diagnostics are now reliable in that they are sensitive 
and specific and more broad-ranging than before. Results 
should now be available while the patient is still in hospital 
or within 36 hours of a GP visit. Critically, a negative result 
is now useful because it is believable, and can radically 
change the clinical perception. The case is surely made 
for its wholescale introduction into laboratories dealing 
with tertiary care facilities. The article by Gunson et al.22 is 
recommended for further reading. However, we believe that 
our goal should be ‘virology for the masses’. Currently, family 
practices do not submit many samples for virology; this is 
completely understandable, considering the long time to any 
result (positive or negative), the low detection rate and the 
Fig. 4. The effect of genetic variability on real-time PCR. Top box: A 
probe based on a parainfluenza strain in The Netherlands was used on 
British strains. Although a peak was apparent (so the primers bound) 
(top left),  the probe did not bind (top right). One base mismatch was 
found on sequencing. Bottom box: Sybr green was incorporated into 
the growing nucleic acid chain and the melt temperature was meas-
ured. Initially, laboratory examples of parainfluenza viruses (1, 2 and 
3) were clearly distinguished. However, a clinical sample (arrowed) 
showed that genetic variability in the wild-type led to failure to cor-
rectly type this strain.
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regular irritating request to ‘submit a second sample’. It is 
our contention that virological examination should become 
a regular part of patient diagnosis and management in the 
community. Samples can be submitted in viral lysis buffer 
(which stabilises nucleic acid); this can be stored for a few 
months and makes the sample non-infectious and thus suitable 
for posting.
There are other advantages to having large numbers of 
samples sourced from primary care. First, Public Health 
would be able to base policy on fact rather than presumption.  
Second, epidemiology of infectious diseases can be studied 
more reliably. Third, with increased understanding of how 
common specific viruses are and what diseases they cause, 
emphasis may shift in research into the most useful vaccines 
and antiviral therapies. Fourth, as antiviral therapies become 
broader in scope and more widely available, it is going to be 
very important to know which viruses are circulating in the 
community and whether or not your patient has that virus.   
In conclusion: many disadvantages have been cited about 
this molecular revolution, but, in our opinion, it is almost 
unethical not to introduce the most sensitive and specific 
assays and to be able to make the most reliable diagnosis. 
Harry Potter came as a saviour of the magical world as PCR 
has waved its wand over clinical virology (although he can 
be as irritating as PCR!). However, the technique does require 
skill and experience, and it is not our contention that it should 
be introduced into every district general hospital, but there 
should be a nationally co-ordinated effort in virology to set up 
specialist centres linking closely with microbiologists in district 
general hospitals. Some molecular assays could be done in 
district general hospitals whereas others would be done at the 
regional centres.
This arrangement, however, leads to the paradox that 
this technology could also be virology’s Lord Voldemort. 
Molecular diagnostics has been driven largely by the world 
of viruses, but it may become so streamlined, efficient and 
foolproof that pressure will mount on all laboratories, however 
small and inexperienced, to introduce such assays. There 
will be substantial commercial pressure to do so. We must 
be wary and ensure that training on how to deal with the 
inevitable failed runs and difficulties in interpretation and 
quality assurance is in place. It will also be important to avoid 
reducing sample numbers submitted to virologists to such a 
degree that it becomes impossible to sustain the momentum in 
the PCR-driven blossoming of virology as a clinically relevant 
speciality.
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